Treatment of disseminated malignant melanoma with high-dose oral BCG
- 15 September 1981
- Vol. 48 (6) , 1353-1362
- https://doi.org/10.1002/1097-0142(19810915)48:6<1353::aid-cncr2820480617>3.0.co;2-n
Abstract
Thirty patients with unresectable disseminated melanoma (Stage IV) were treated with Bacillus Calmette-Guerin (BCG) (Moreau strain—Rio de Janeiro) by mouth, with weekly doses ranging between 200 mg and 28,000 mg. Five patients died in the first two months of treatment. Of the remaining 25 patients, two (8%) showed complete regression, and one (4%) partial regression. Seven patients (28%) had stabilization of the disease for a six-month period, and 15 (60%) had progression of the disease. Complete and partial regressions were seen only in patients with extravisceral (subcutaneous) metastases, and were associated with a longer survival time. Regression of the subcutaneous metastatic nodules was always accompanied by the following local phenomena: increased temperature; local inflammation; softening, pain and pruritus at the nodule site; and a gradual decrease in size. At the site of the tumor mass, a hypochromic halo appeared. This halo remained permanently and was pathognomonic of the metastatic nodule rejection. When the halo was fully established, the inflammatory infiltrate was minimal and the malignant cells disappeared. If the area contained hairs, they underwent complete albinization. Serial biopsies of the nodules undergoing inflammatory changes and decreased consistency exhibited an intense cellular infiltration of lymphocytes, macrophages, and plasma cells around the malignant cells. This sometimes simulated lymphoid follicle formation involving the melanoma cells associated with necrosis in a centripetal way. Some patients with visceral metastases (particularly pulmonary) had an unexpectedly long survival, apparently associated with interruption of the growth rate of the masses. Eleven out of 20 deaths were due to cerebral metastases. When cerebral disease was diagnosed, BCG was discontinued and the administration of corticoids was usually associated with a disappearance of the inflammatory signs at the nodule sites, but with progression of the disease. Toxicity was minimal.This publication has 21 references indexed in Scilit:
- Hazards and Complications of BCG ImmunotherapyMedical Clinics of North America, 1976
- Intralesional Immunotherapy of Melanoma with BCGMedical Clinics of North America, 1976
- Influence of orally administered B.C.G. on growth of transplanted rat tumoursBritish Journal of Cancer, 1975
- Suppression of transplanted rat sarcomata mediated by Bacillus Calmette Guérin (BCG)Published by Elsevier ,1974
- BCG Immunotherapy of a Rat SarcomaBritish Journal of Cancer, 1973
- Cell-Mediated Immunity to Human TumorsArchives of Surgery, 1973
- BCG Immunotherapy of Pulmonary Growths from Intravenously Transferred Rat Tumour CellsBritish Journal of Cancer, 1973
- Immunological Effects of BCG in Malignant Melanoma: Two Modes of Administration ComparedAnnals of Internal Medicine, 1972
- Demonstration of cell‐mediated immunity to human neoplasms of various histological typesInternational Journal of Cancer, 1971
- Detection by immunofluorescenge of antibodies specific for human malignant melanoma cellsCancer, 1969